Trial intelligence / Profile preview

Antineoplastons A10 and AS2-1 in Stage IV Bladder Cancer

NCT00003452Phase 2Terminated

Sponsor
Burzynski Research Institute
Start
May 1996
Primary completion
May 1998
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in bladder cancer, sponsored by Burzynski Research Institute. Started May 1996; status: terminated.

02

Drugs

antineoplaston A10antineoplaston AS2-1
03

Conditions

bladder cancer

Beyond the preview

Go deeper on NCT00003452.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00003452.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call